Clinical TrialsNo new safety signals have been observed in the POTENTIATE trial, indicating a favorable safety profile for the ongoing research.
Financial StabilityBOLD reports cash and cash equivalents of $167.1 million, which provides a cash runway into 4Q26, ensuring financial stability for continued operations and research.
Innovative ResearchBOLD authored a Nature publication demonstrating the rationale for CHK1 inhibition as an ecDNA-targeted therapy, highlighting their innovative approach in cancer treatment.